Key insights
- OnKure Therapeutics CFO Jason Leverone sold $898 in stock to cover tax obligations related to RSUs. The sale occurred as the stock trades near its 52-week low, despite analyst price targets suggesting undervaluation. Separately, H.C. Wainwright lowered its price target for OnKure to $21 from $27 but maintained a Buy rating, following the presentation of preclinical data for its PI3Kα inhibitors which showed greater cellular selectivity than competitors' drugs.
Jason A. Leverone, Chief Financial Officer of OnKure Therapeutics, Inc. (NASDAQ:OKUR), sold 302 shares of Class A Common Stock on September 21, 2026, for a total value of $898. The shares were sold at prices ranging from $2.95 to $3.06, with a weighted average sale price of $2.9742 per share. The stock currently trades at $2.90, down 27% over the past six months and near its 52-week low of $2.23, though analysts maintain price targets between $11 and $21, according to InvestingPro data, which suggests the stock may be undervalued at current levels.
The sale was conducted to cover tax withholding obligations in connection with the vesting of restricted stock units (RSUs), pursuant to the terms of the Issuer’s 2023 RSU Equity Incentive Plan. Following this transaction, Mr. Leverone directly beneficially owns 18,500 shares of OnKure Therapeutics Class A Common Stock. Certain of these securities are RSUs, where each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions.
In other recent news, H.C. Wainwright has adjusted its price target for OnKure Therapeutics Inc. to $21, down from $27, while maintaining a Buy rating. The revision follows OnKure’s presentation of preclinical data for its pan-mutant PI3Kα inhibitors, OKI-345 and OKI-355. These agents demonstrated significantly greater cellular selectivity in specific cell lines compared to competitors Eli Lilly’s tersolisib and Relay Therapeutics’ zovegalisib. This development is part of the company’s ongoing efforts to advance its therapeutic pipeline. The adjustment in valuation reflects the firm’s response to the new data presented. Investors may find this information relevant as it impacts the company’s projected financial outlook. Such updates are crucial for understanding the evolving landscape of OnKure’s product development.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Our Fair Value model runs 17 proven valuation methods on OKUR and returns one number: what the stock is worth today, and how far the current price sits from it.Same calculation on thousands of other stocks — so you can see instantly whether OKUR is the best value on the table, or whether something cheaper is hiding in plain sight.